Genor Biopharma Holdings Limited Stock

Equities

6998

KYG3871A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:13 2024-07-03 am EDT 5-day change 1st Jan Change
1.06 HKD -7.02% Intraday chart for Genor Biopharma Holdings Limited -9.40% -10.92%

Financials

Sales 2022 15.93M 2.19M 17.11M Sales 2023 - Capitalization 545M 74.93M 585M
Net income 2022 -730M -100M -784M Net income 2023 -674M -92.69M -724M EV / Sales 2022 -24.3 x
Net cash position 2022 1.56B 215M 1.68B Net cash position 2023 1.16B 159M 1.24B EV / Sales 2023 -
P/E ratio 2022
-1.62 x
P/E ratio 2023
-0.81 x
Employees 104
Yield 2022 *
-
Yield 2023
-
Free-Float 66.16%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.02%
1 week-9.40%
Current month-7.02%
1 month-17.83%
3 months-4.50%
6 months-3.64%
Current year-10.92%
More quotes
1 week
1.06
Extreme 1.06
1.19
1 month
1.06
Extreme 1.06
1.39
Current year
0.85
Extreme 0.85
1.55
1 year
0.85
Extreme 0.85
1.73
3 years
0.85
Extreme 0.85
17.32
5 years
0.85
Extreme 0.85
32.20
10 years
0.85
Extreme 0.85
32.20
More quotes
Date Price Change Volume
24-07-03 1.06 -7.02% 406 000
24-07-02 1.14 0.00% 0
24-06-28 1.14 0.00% 54,000
24-06-27 1.14 -2.56% 175,000
24-06-26 1.17 +0.86% 85,500

Delayed Quote Hong Kong S.E., July 03, 2024 at 04:08 am EDT

More quotes
Genor Biopharma Holdings Ltd, formerly JHBP CY Holdings Ltd, is China-based company mainly engaged in the research and development of biopharmaceutical products. The Company focuses on the development and commercialization of oncology and autoimmune drugs. The Company's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The Company mainly conducts its businesses in the China market.
More about the company